Return to homepagePandemic Pact

Preclinical development of an antiviral small molecule drug against COVID-19

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:0 publications

Grant number: 1.04302E+13

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2023
    2025

  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)

  • Principal Investigator

    dr B. van Buuren

  • Research Location

    Netherlands

  • Lead Research Institution

    Radboud Universiteit Nijmegen

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The recent COVID-19 pandemic has shown how vulnerable we are as a society and how difficult it is to defend ourselves against infections with new types of viruses. SARS-CoV-2 has not been eradicated by vaccinations and some patients suffer from severe COVID-19 and/or long COVID symptoms. However, the (preventive) use of antiviral medicines to treat these patients is still limited. In this project, subsidized by ZonMw, Radboud University, Protinhi Therapeutics and Artemis Bioservices will improve viral control by developing an innovative antiviral agent. This medicine targets viral proteases, enzymes that are crucial for the replication of the virus once it has entered the body. Since viral proteases are highly conserved among coronaviruses, the project will also contribute to pandemic preparedness against future coronavirus outbreaks.